Generation and characterization of diverse modality ADCs

Explore ChemPartner’s research on next-generation antibody-drug conjugates (ADCs), including monospecific, bispecific, biparatopic, dual-payload, and trispecific modalities. See how multispecific designs improve internalization, cytotoxicity, and therapeutic efficacy, addressing tumor heterogeneity and drug resistance in cancer therapy.